Back to search results

A Study of CD8+ T Cell Imaging in Non-Small Cell Lung Cancer

This study is looking at a new way to see specific immune cells called CD8+ T cells in people with metastatic non-small cell lung cancer. Researchers want to see if a special imaging agent, Zirconium Zr 89 crefmirlimab berdoxam, combined with PET/CT scans (positron emission tomography/computed tomography scans), can safely and effectively identify these cells. You could be eligible if you are 18 or older, have metastatic non-small cell lung cancer, and are already enrolled in another specific cell therapy study (OBX115-23-01) but haven't started treatment yet. The main goal is to see how the imaging agent uptake changes before and after cell therapy. The current recruitment status is unclear, and the study plans to enroll 5 participants.

Study design
This is an interventional study with an unclear phase, planning to enroll 5 participants. It involves using an imaging agent and PET/CT scans.
What's involved
You would receive up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam, each followed by a PET/CT scan about 24 hours later.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured from baseline to two weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06863233

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

Completed
PHASE1Ages 18+InterventionalDiagnostic
Memorial Sloan Kettering Cancer Center
~4 participants
Updated 2026-08-26 on ClinicalTrials.gov
What's tested:Zirconium Zr 89 crefmirlimab berdoxamPET/CT Scan

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Difference between Zirconium Zr 89 crefmirlimab berdoxam PET uptake at pre- vs post-TIL infusion and pre- vs post-ACZ redosing.
Measured over Baseline to two weeks

Conditions

Lung Cancer
Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Adam Schoenfeld, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient must be 18 years of age or older at the time of signing the informed consent.
Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer
Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet.
Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product.
Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
Patient or legally authorized representative provided written authorization for use and disclosure of protected health information.

Exclusion

Pregnant or breastfeeding women
Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)

What this trial measures

  • Difference between Zirconium Zr 89 crefmirlimab berdoxam PET uptake at pre- vs post-TIL infusion and pre- vs post-ACZ redosing.Baseline to two weeks

    Assess the distribution of the CD8+ cells during TIL therapy by measuring the largest difference in Zirconium Zr 89 crefmirlimab berdoxam PET uptake at pre- vs post-TIL infusion and pre- vs post-ACZ redosing.